About Butyrophilin-like protein 2
Butyrophilin-like protein 2 (BTNL2) is a protein
from Homo sapiens identified by UniProt accession
Q9UIR0, 482 residues long.
MolForge cross-references it against 0 known binders and
174 disease associations.
Target properties
| Protein name | Butyrophilin-like protein 2 |
| UniProt accession | Q9UIR0 |
| Gene | BTNL2 |
| Organism | Homo sapiens |
| Length | 482 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (174)
Diseases linked to this target (Open Targets).
- BMI-adjusted waist-hip ratio · score 0.34
- blood protein measurement · score 0.32
- Epstein Barr virus nuclear antigen 1 IgG measurement · score 0.31
- hepatitis C induced liver cirrhosis · score 0.31
- Vitiligo · score 0.31
- sarcoidosis · score 0.30
- lung adenocarcinoma · score 0.30
- response to vaccine · score 0.29
- Crohn's disease · score 0.28
- nephrotic syndrome · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UIR0-F1 | alphafold | PREDICTED | 85.86 | — |
Amino-acid sequence (482 residues)
MVDFPGYNLS GAVASFLFIL LTMKQSEDFR VIGPAHPILA GVGEDALLTC QLLPKRTTMH VEVRWYRSEP STPVFVHRDG VEVTEMQMEE YRGWVEWIEN GIAKGNVALK IHNIQPSDNG QYWCHFQDGN YCGETSLLLK VAGLGSAPSI HMEGPGESGV QLVCTARGWF PEPQVYWEDI RGEKLLAVSE HRIQDKDGLF YAEATLVVRN ASAESVSCLV HNPVLTEEKG SVISLPEKLQ TELASLKVNG PSQPILVRVG EDIQLTCYLS PKANAQSMEV RWDRSHRYPA VHVYMDGDHV AGEQMAEYRG RTVLVSDAID EGRLTLQILS ARPSDDGQYR CLFEKDDVYQ EASLDLKVVS LGSSPLITVE GQEDGEMQPM CSSDGWFPQP HVPWRDMEGK TIPSSSQALT QGSHGLFHVQ TLLRVTNISA VDVTCSISIP FLGEEKIATF SLSESRMTFL WKTLLVWGLL LAVAVGLPRK RS
Explore Butyrophilin-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets